15145-38-7

Usage

Uses

Used in Oncology:
N-(4-BROMOPHENYL)-N'-(2-CHLOROETHYL)UREA is used as a potential anti-cancer agent for its ability to target and inhibit the growth of cancer cells. N-(4-BROMOPHENYL)-N'-(2-CHLOROETHYL)UREA's alkylating properties allow it to form covalent bonds with cellular macromolecules, particularly DNA, causing damage that leads to cell death.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, N-(4-BROMOPHENYL)-N'-(2-CHLOROETHYL)UREA serves as a subject of ongoing research for the development of novel anti-cancer drugs. Its unique structure and functional groups make it a promising candidate for the design of new therapeutic agents that can effectively combat various types of cancer.
Used in Drug Development:
N-(4-BROMOPHENYL)-N'-(2-CHLOROETHYL)UREA is utilized in the pharmaceutical industry for the development of new drugs targeting cancer treatment. Its cytotoxic effects and ability to induce apoptosis in cancer cells make it a valuable component in the creation of innovative cancer therapies.
Used in Cancer Treatment:
N-(4-BROMOPHENYL)-N'-(2-CHLOROETHYL)UREA is employed as a therapeutic agent in cancer treatment, specifically for its potential to target and eliminate cancerous cells. N-(4-BROMOPHENYL)-N'-(2-CHLOROETHYL)UREA's interaction with cellular DNA and proteins results in the inhibition of cell growth and the promotion of cell death, offering a promising approach to treating various types of cancer.

Upstream product

• 1943-83-5 2-chloroethyl isothiocyanate 
• 106-40-1 4-bromo-aniline 

Relevant academic research and scientific papers

AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION

This invention provides amine-linked C3-glutarimide Degronimers and Degrons for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation.

CYCLIC UREAS AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Antimitotic antitumor agents: Synthesis, structure-activity relationships, and biological characterization of N-aryl-N′-(2-chloroethyl)ureas as new selective alkylating agents

A series of N-aryl-N′-(2-chloroethyl)ureas (CEUs) and derivatives were synthesized and evaluated for antiproliferative activity against a wide panel of tumor cell lines. Systematic structure-activity relationship (SAR) studies indicated that: (i) a branched alkyl chain or a halogen at the 4-position of the phenyl ring or a fluorenyl/indanyl group, (ii) an exocyclic urea function, and (iii) a N′-2-chloroethyl moiety were required to ensure significant cytotoxicity. Biological experiments, such as immunofluorescence microscopy, confirmed that these promising compounds alter the cytoskeleton by inducing microtubule depolymerization via selective alkylation of β-tubulin. Subsequent evaluations demonstrated that potent CEUs were weak alkylators, were non-DNA-damaging agents, and did not interact with the thiol function of either glutathione or glutathione reductase. Therefore, CEUs are part of a new class of antimitotic agents. Finally, among the series of CEUs evaluated, compounds 12, 15, 16, and 27 were selected for further in vivo trials.